Literature DB >> 11419509

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.

J R Groothuis1.   

Abstract

An Expanded Access Study was conducted to collect additional safety data on palivizumab. Preterm infants with or without bronchopulmonary dysplasia received palivizumab every 30 days during the respiratory syncytial virus season. Adverse events were low (6.9%) in the 565 subjects. Serious adverse events included hospitalization and 1 case of respiratory syncytial virus bronchiolitis not requiring hospitalization. This study reaffirms the safety and tolerability of palivizumab.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11419509     DOI： 10.1097/00006454-200106000-00018

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  13 in total

Review 1.  Palivizumab for preterm infants. Is it worth it?

Authors:  N D Embleton; C Harkensee; M C Mckean
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-07       Impact factor: 5.747

Review 2.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

3.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Authors:  J E Ledgerwood; E E Coates; G Yamshchikov; J G Saunders; L Holman; M E Enama; A DeZure; R M Lynch; I Gordon; S Plummer; C S Hendel; A Pegu; M Conan-Cibotti; S Sitar; R T Bailer; S Narpala; A McDermott; M Louder; S O'Dell; S Mohan; J P Pandey; R M Schwartz; Z Hu; R A Koup; E Capparelli; J R Mascola; B S Graham
Journal:  Clin Exp Immunol       Date:  2015-09-24       Impact factor: 4.330

4.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Authors:  Caroline Fenton; Lesley J Scott; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 5.  Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Authors:  Colleen Wegzyn; Lim Kai Toh; Gerard Notario; Sophie Biguenet; Kristina Unnebrink; Caroline Park; Doris Makari; Michael Norton
Journal:  Infect Dis Ther       Date:  2014-10-09

Review 6.  Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.

Authors:  Eric A F Simões; Louis Bont; Paolo Manzoni; Brigitte Fauroux; Bosco Paes; Josep Figueras-Aloy; Paul A Checchia; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2018-02-22

7.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03

Review 8.  Immunoprophylaxis of respiratory syncytial virus: global experience.

Authors:  Eric A F Simoes
Journal:  Respir Res       Date:  2002

9.  Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.

Authors:  Jinghan Jenny Chen; Parco Chan; Bosco Paes; Ian Mitchell; Abby Li; Krista L Lanctôt
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

10.  A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.

Authors:  Hsin Chi; Chyong-Hsin Hsu; Jui-Hsing Chang; Nan-Chang Chiu; Han-Yang Hung; Hsin-An Kao; Li-Chuan Weng; Fu-Yuan Huang; Yu-Ying Chiu; Luan-Yin Chang; Li-Min Huang
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.